Lexaria Bioscience Announces Additional Interim Results From Human Pilot Study Evaluating Dehydratechtm Technology For The Oral Delivery Of The Glucagon-Like Peptide-1 Drug Semaglutide Available In The Branded Product Rybelsus
Portfolio Pulse from Benzinga Newsdesk
Lexaria Bioscience reported interim results from a human pilot study evaluating its DehydraTECH technology for oral delivery of semaglutide, a drug found in Rybelsus. The study showed that DehydraTECH-powered semaglutide sustained lower blood glucose levels, including nearly 10 times lower after 24 hours, and reduced blood-glucose spikes after eating. This marks the first successful DehydraTECH test with a large molecule drug.
November 28, 2023 | 2:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lexaria Bioscience's positive interim study results for DehydraTECH technology in delivering semaglutide could boost investor confidence and potentially increase the stock's value in the short term.
The positive interim results from the human pilot study are significant as they demonstrate the potential of Lexaria's DehydraTECH technology to improve the delivery of semaglutide, a diabetes medication. This could lead to increased interest from investors due to the potential market implications and partnerships, thus possibly driving up the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100